MedTrace Logo

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05393466 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-07

No results posted yet for this study

Summary

This is a three-stage study, consisting of Phase Ia dose-escalation, Phase Ib dose expansion, and a Phase II component.

Conditions

  • Non-small Cell Lung Carcinoma

Interventions

DRUG

BPI-361175

BPI-361175 is an oral fourth-generation EGFR inhibitor. The activation of EGFR signaling pathways is associated with various biological events such as proliferation, migration, differentiation, and apoptosis.

Sponsors & Collaborators

  • Xcovery Holdings, Inc.

    lead INDUSTRY

Principal Investigators

  • Giovanni C Selvaggi, MD · Xcovery Holdings, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2028-01-30
Completion
2029-05-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05393466 on ClinicalTrials.gov